%0 Journal Article
%T Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
%A Christian H. Ottensmeier
%A Edurne Arriola
%A Ioannis Karydis
%A Matthew Wheater
%A Peter W. Szlosarek
%A Pui Ying Chan
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2016.1143997
%X Background: Untreated metastatic uveal melanoma (UM) carries a grave prognosis. Unlike cutaneous melanoma (CM), there are no established treatments known to significantly improve outcomes for a meaningful proportion of patients. Inhibition of the PD1¨CPDL1 axis has shown promise in the management of CM and we here report a two center experience of UM patients receiving pembrolizumab. Methods: To assess the efficacy and safety of pembrolizumab, we retrospectively analyzed outcome data of 25 consecutive UM patients participating in the MK3475 expanded access program (EAP) who received pembrolizumab at 2 mg/kg 3 weekly. Tumor assessment was evaluated using RECIST 1.1 and immune-related Response Criteria (irRC) by CT scanning. Toxicity was recorded utilizing Common Terminology Criteria for Adverse Events (ˇ°CTCAEˇ±) v4.03. Results: Twenty-five patients were identified receiving a median of six cycles of treatment. Two patients achieved a partial response and six patients stable disease. After a median follow-up of 225 d median progression free survival (PFS) was 91 d and overall survival (OS) was not reached. There was a significant trend for improved outcomes in patients with extrahepatic disease progression as opposed to liver only progression at the outset. Five patients experienced grade 3 or 4 adverse events (AEs); there were no treatment related deaths. Conclusions: Pembrolizumab 2mg/kg q3w is a safe option in UM patients. Disease control rates, particularly in the subgroup of patients without progressive liver disease at the outset are promising; these results merit further investigation in clinical trials possibly incorporating liver targeted treatment modalities
%K Anti-PD-1
%K immuno-oncology
%K metastases
%K Pembrolizumab
%K uveal melanoma
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910726/